US20060258686A1
(en)
*
|
1998-05-29 |
2006-11-16 |
Cheresh David A |
Method of treatment of myocardial infarction
|
US20030130209A1
(en)
*
|
1999-12-22 |
2003-07-10 |
Cheresh David A. |
Method of treatment of myocardial infarction
|
BR0007532A
(pt)
|
1999-01-13 |
2001-11-20 |
Univ New York State Res Found |
Métodos para identificar inibidores de proteìnaquinase, para testar compostos para umacapacidade de inibir a atividade de proteìnaquinase e para inibir uma proteìna quinase, inibidorde proteìna tirosina quinase não peptìdica, e,método de tratar uma condição responsiva a uminibidor de proteìna quinase em um paciente
|
US7223724B1
(en)
|
1999-02-08 |
2007-05-29 |
Human Genome Sciences, Inc. |
Use of vascular endothelial growth factor to treat photoreceptor cells
|
ATE253918T1
(de)
|
1999-12-08 |
2003-11-15 |
Centre Nat Rech Scient |
Verwendung von hymenialdisin und dessen derivaten zur herstellung therapeutischer mittel
|
US7273751B2
(en)
*
|
2000-08-04 |
2007-09-25 |
Human Genome Science, Inc. |
Vascular endothelial growth factor-2
|
MXPA03008560A
(es)
*
|
2001-03-22 |
2004-06-30 |
Abbot Gmbh & Co Kg |
Pirazolopirimidinas como agentes terapeuticos.
|
ATE470676T1
(de)
*
|
2001-04-13 |
2010-06-15 |
Human Genome Sciences Inc |
Anti-vegf-2 antikörper
|
US20050232921A1
(en)
*
|
2001-04-13 |
2005-10-20 |
Rosen Craig A |
Vascular endothelial growth factor 2
|
AU2002252631A1
(en)
*
|
2001-04-13 |
2002-10-28 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
JP4623962B2
(ja)
*
|
2001-10-22 |
2011-02-02 |
ザ・リサーチ・ファウンデーション・オブ・ステイト・ユニバーシティ・オブ・ニューヨーク |
タンパク質キナーゼおよびホスファターゼ阻害剤、それらを設計する方法、ならびにそれらを使用する方法
|
US7005445B2
(en)
|
2001-10-22 |
2006-02-28 |
The Research Foundation Of State University Of New York |
Protein kinase and phosphatase inhibitors and methods for designing them
|
US20030199525A1
(en)
*
|
2002-03-21 |
2003-10-23 |
Hirst Gavin C. |
Kinase inhibitors
|
MXPA05001389A
(es)
|
2002-08-06 |
2005-04-28 |
Astrazeneca Ab |
Piridinas y pirimidinas condensadas con actividad tie2 (tek).
|
WO2004065380A1
(en)
|
2003-01-14 |
2004-08-05 |
Arena Pharmaceuticals Inc. |
1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
|
AU2004221812B2
(en)
*
|
2003-03-19 |
2010-02-18 |
Exelixis Inc. |
Tie-2 modulators and methods of use
|
US20050008640A1
(en)
*
|
2003-04-23 |
2005-01-13 |
Wendy Waegell |
Method of treating transplant rejection
|
US7429596B2
(en)
*
|
2003-06-20 |
2008-09-30 |
The Regents Of The University Of California |
1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
|
AR045037A1
(es)
|
2003-07-10 |
2005-10-12 |
Aventis Pharma Sa |
Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
|
EP1644375A2
(en)
*
|
2003-07-14 |
2006-04-12 |
Arena Pharmaceuticals, Inc. |
Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
|
DE10344223A1
(de)
*
|
2003-09-24 |
2005-04-21 |
Merck Patent Gmbh |
1,3-Benzoxazolylderivate als Kinase-Inhibitoren
|
GB0401334D0
(en)
*
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
CA2553724A1
(en)
*
|
2004-02-03 |
2005-08-18 |
Abbott Laboratories |
Aminobenzoxazoles as therapeutic agents
|
WO2006068760A2
(en)
*
|
2004-11-19 |
2006-06-29 |
The Regents Of The University Of California |
Anti-inflammatory pyrazolopyrimidines
|
DOP2006000009A
(es)
*
|
2005-01-13 |
2006-08-15 |
Arena Pharm Inc |
Procedimiento para preparar eteres de pirazolo [3,4-d] pirimidina
|
PL2987796T3
(pl)
*
|
2005-02-16 |
2018-12-31 |
Anacor Pharmaceuticals, Inc. |
Fluorowco-podstawione boronoftalidy do leczenia zakażeń
|
US8143285B2
(en)
|
2005-09-06 |
2012-03-27 |
Shionogi & Co., Ltd. |
Indolecarboxylic acid derivative having PGD2 receptor antagonistic activity
|
ES2436877T3
(es)
*
|
2005-11-17 |
2014-01-07 |
OSI Pharmaceuticals, LLC |
Intermedios para la preparación de inhibidores de mTOR bicíclicos condensados
|
KR101324737B1
(ko)
|
2005-12-13 |
2013-11-05 |
인사이트 코포레이션 |
야누스 키나아제 억제제로서의 헤테로아릴 치환된 피롤로[2,3-b]피리딘 및 피롤로[2,3-b]피리미딘
|
WO2007087068A2
(en)
*
|
2006-01-13 |
2007-08-02 |
Pharmacyclics, Inc. |
Inhibitors of tyrosine kinases and uses thereof
|
JP5156644B2
(ja)
*
|
2006-01-25 |
2013-03-06 |
オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー |
不飽和mTOR阻害剤
|
WO2007103308A2
(en)
*
|
2006-03-07 |
2007-09-13 |
Array Biopharma Inc. |
Heterobicyclic pyrazole compounds and methods of use
|
KR20090017498A
(ko)
*
|
2006-04-04 |
2009-02-18 |
더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 |
Pi3 키나제 길항물질
|
WO2007139952A2
(en)
*
|
2006-05-25 |
2007-12-06 |
Synta Pharmaceuticals Corp. |
Method for the preparation of triazole compounds with hsp90 modulating activity
|
US7838542B2
(en)
|
2006-06-29 |
2010-11-23 |
Kinex Pharmaceuticals, Llc |
Bicyclic compositions and methods for modulating a kinase cascade
|
US20080114063A1
(en)
*
|
2006-08-16 |
2008-05-15 |
Action Medicines |
Use of 2,5-Dihydroxybenzene Derivatives for the Treatment of Tissue Reactive Diseases
|
PT2530083T
(pt)
*
|
2006-09-22 |
2016-08-01 |
Pharmacyclics Llc |
Inibidores de tirosina cinase de bruton
|
ES2403546T3
(es)
*
|
2006-11-03 |
2013-05-20 |
Pharmacyclics, Inc. |
Sonda de actividad de la tirosina-cinasa de Bruton y procedimiento de utilización
|
EP2099444A4
(en)
*
|
2006-12-14 |
2012-11-07 |
Nps Pharma Inc |
USE OF D-SERIN DERIVATIVES FOR THE TREATMENT OF ANTIBODIES
|
ATE528286T1
(de)
|
2006-12-20 |
2011-10-15 |
Bayer Healthcare Llc |
4-ä4-ä(ä3-tert-butyl-1-ä3-(hydroxymethyl)phenyl - 1h-pyrazol-5-ylücarbamoyl)-aminoü-3- chlorophenoxyü-n-methylpyridin-2-carboxamid als inhibitor der vegfr kinase zur behandlung von krebs
|
EP2099442B1
(en)
*
|
2006-12-26 |
2014-11-19 |
Pharmacyclics, Inc. |
Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
|
WO2008093246A2
(en)
*
|
2007-02-02 |
2008-08-07 |
Vegenics Limited |
Vegf receptor antagonist for treating organ transplant alloimmunity and arteriosclerosis
|
US20120101114A1
(en)
|
2007-03-28 |
2012-04-26 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
WO2008153701A1
(en)
*
|
2007-05-24 |
2008-12-18 |
Schering Corporation |
Compounds for inhibiting ksp kinesin activity
|
CU24179B1
(es)
|
2007-06-13 |
2016-04-25 |
Incyte Corp |
SALES DE ÁCIDO MALEICO Y DE ÁCIDO SULFÚRICO DE (R)-3-(4-(7H-PIRROLO[2,3-d]PIRIMIDIN-4-IL)-1H-PIRAZOL-1-IL)-3-CICLOPENTILPROPANITRILO
|
GB2467670B
(en)
|
2007-10-04 |
2012-08-01 |
Intellikine Inc |
Chemical entities and therapeutic uses thereof
|
CA2709879A1
(en)
*
|
2007-12-19 |
2009-06-25 |
The Scripps Research Institute |
Anilides and analogs as rho kinase inhibitors
|
WO2009079008A1
(en)
*
|
2007-12-19 |
2009-06-25 |
Yangbo Feng |
Benzopyrans and analogs as rho kinase inhibitors
|
MX2010007419A
(es)
|
2008-01-04 |
2010-11-12 |
Intellikine Inc |
Ciertas entidades quimicas, composiciones y metodos.
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
US20110092452A1
(en)
*
|
2008-03-05 |
2011-04-21 |
The Regents Of The University Of Michigan |
Compositions and methods for diagnosing and treating pancreatic cancer
|
JP5547099B2
(ja)
|
2008-03-14 |
2014-07-09 |
インテリカイン, エルエルシー |
キナーゼ阻害剤および使用方法
|
WO2009114874A2
(en)
*
|
2008-03-14 |
2009-09-17 |
Intellikine, Inc. |
Benzothiazole kinase inhibitors and methods of use
|
EA018144B1
(ru)
*
|
2008-03-19 |
2013-05-30 |
Оси Фармасьютикалз, Инк. |
СОЛЕВЫЕ ФОРМЫ ИНГИБИТОРА mTOR
|
US20090301928A1
(en)
*
|
2008-06-05 |
2009-12-10 |
United Comb & Novelty Corporation |
Packaging For Lipped Containers
|
BRPI0915231A2
(pt)
|
2008-07-08 |
2018-06-12 |
Intellikine Inc |
compostos inibidores de quinase e métodos de uso
|
US20110224223A1
(en)
|
2008-07-08 |
2011-09-15 |
The Regents Of The University Of California, A California Corporation |
MTOR Modulators and Uses Thereof
|
EP3311818A3
(en)
*
|
2008-07-16 |
2018-07-18 |
Pharmacyclics, LLC |
Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
|
EP2346508B1
(en)
|
2008-09-26 |
2016-08-24 |
Intellikine, LLC |
Heterocyclic kinase inhibitors
|
DK2358720T3
(en)
*
|
2008-10-16 |
2016-06-06 |
Univ California |
Heteroarylkinaseinhibitorer fused-ring
|
EP2352501B1
(en)
*
|
2008-11-03 |
2014-01-01 |
ChemoCentryx, Inc. |
Compounds for use in the treatment of osteoporosis
|
US8476282B2
(en)
*
|
2008-11-03 |
2013-07-02 |
Intellikine Llc |
Benzoxazole kinase inhibitors and methods of use
|
US8426428B2
(en)
*
|
2008-12-05 |
2013-04-23 |
Principia Biopharma, Inc. |
EGFR kinase knockdown via electrophilically enhanced inhibitors
|
JP5789252B2
(ja)
|
2009-05-07 |
2015-10-07 |
インテリカイン, エルエルシー |
複素環式化合物およびその使用
|
EA020494B1
(ru)
|
2009-05-22 |
2014-11-28 |
Инсайт Корпорейшн |
3-[4-(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1H-ПИРАЗОЛ-1-ИЛ]ОКТАН- ИЛИ ГЕПТАННИТРИЛ КАК JAK-ИНГИБИТОРЫ
|
BRPI1012159B1
(pt)
|
2009-05-22 |
2022-01-25 |
Incyte Holdings Corporation |
Compostos derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d] pirimidinas e pirrol-3-il-pirrolo[2,3-d] pirimidinas como inibidores de janus cinase, composições farmacêuticas compreendendo os referidos compostos e usos dos mesmos
|
JP6073677B2
(ja)
|
2009-06-12 |
2017-02-01 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
縮合複素環式化合物およびそれらの使用
|
MX2012002066A
(es)
|
2009-08-17 |
2012-03-29 |
Intellikine Inc |
Compuestos heterociclicos y usos de los mismos.
|
TW201113285A
(en)
|
2009-09-01 |
2011-04-16 |
Incyte Corp |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
JP2013506686A
(ja)
|
2009-09-30 |
2013-02-28 |
プレジデント アンド フェロウズ オブ ハーバード カレッジ |
オートファジー阻害遺伝子産物の変調によりオートファジーを変調する方法
|
US7741330B1
(en)
|
2009-10-12 |
2010-06-22 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
|
WO2011047384A2
(en)
|
2009-10-16 |
2011-04-21 |
The Regents Of The University Of California |
Methods of inhibiting ire1
|
EP2947073B1
(en)
|
2009-10-22 |
2019-04-03 |
Fibrotech Therapeutics Pty Ltd |
Fused ring analogues of anti-fibrotic agents
|
US20110130711A1
(en)
*
|
2009-11-19 |
2011-06-02 |
Follica, Inc. |
Hair growth treatment
|
US9180127B2
(en)
|
2009-12-29 |
2015-11-10 |
Dana-Farber Cancer Institute, Inc. |
Type II Raf kinase inhibitors
|
EP3378854B1
(en)
|
2010-01-27 |
2022-12-21 |
Arena Pharmaceuticals, Inc. |
Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
|
MX2012009377A
(es)
|
2010-02-11 |
2012-09-12 |
Univ Vanderbilt |
Benzotiazoles y azabenzotiazoles como potenciadores alostericos mglur4, composiciones y metodos para tratar la disfuncion neurologica.
|
NO3050882T3
(pl)
*
|
2010-03-10 |
2018-06-30 |
|
|
EP2560640A1
(en)
|
2010-04-19 |
2013-02-27 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
|
CA2799579A1
(en)
|
2010-05-21 |
2011-11-24 |
Intellikine, Inc. |
Chemical compounds, compositions and methods for kinase modulation
|
EP2574168B9
(en)
|
2010-05-21 |
2016-10-05 |
Incyte Holdings Corporation |
Topical formulation for a jak inhibitor
|
JP5892550B2
(ja)
*
|
2010-05-24 |
2016-03-23 |
トーアエイヨー株式会社 |
縮合イミダゾール誘導体
|
NZ717373A
(en)
|
2010-06-03 |
2017-11-24 |
Pharmacyclics Llc |
The use of inhibitors of bruton’s tyrosine kinase (btk)
|
WO2012003544A1
(en)
*
|
2010-07-09 |
2012-01-12 |
The Walter And Eliza Hall Institute Of Medical Research |
Protein kinase inhibitors and methods of treatment
|
PE20131371A1
(es)
|
2010-09-22 |
2013-11-25 |
Arena Pharm Inc |
Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con este
|
CA2817577A1
(en)
|
2010-11-10 |
2012-05-18 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
UA113156C2
(xx)
|
2010-11-19 |
2016-12-26 |
|
Циклобутилзаміщені похідні піролопіридину й піролопіримідину як інгібітори jak
|
TWI546305B
(zh)
|
2011-01-10 |
2016-08-21 |
英菲尼提製藥股份有限公司 |
製備異喹啉酮之方法及異喹啉酮之固體形式
|
WO2012148540A1
(en)
|
2011-02-23 |
2012-11-01 |
Intellikine, Llc |
Combination of kanase inhibitors and uses threof
|
EA201490042A1
(ru)
|
2011-06-20 |
2014-10-30 |
Инсайт Корпорейшн |
Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak
|
ES2624981T3
(es)
|
2011-07-01 |
2017-07-18 |
Dana-Farber Cancer Institute, Inc. |
Descubrimiento de una mutación somática en el gen MYD88 en linfoma linfoplasmocitario
|
JP2014520863A
(ja)
|
2011-07-13 |
2014-08-25 |
ファーマサイクリックス,インク. |
Bruton型チロシンキナーゼの阻害剤
|
AU2012284091B2
(en)
|
2011-07-19 |
2015-11-12 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
AU2012284088B2
(en)
|
2011-07-19 |
2015-10-08 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
EP2548877A1
(en)
*
|
2011-07-19 |
2013-01-23 |
MSD Oss B.V. |
4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
|
KR101702727B1
(ko)
|
2011-07-19 |
2017-02-06 |
머크 샤프 앤 도메 비.브이. |
Btk-억제제로서의 4-이미다조피리다진-1-일-벤즈아미드 및 4-이미다조트리아진-1-일-벤즈아미드
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為jak抑制劑之環己基氮雜環丁烷衍生物
|
EP2751093A1
(en)
|
2011-08-29 |
2014-07-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
EP2751112B1
(en)
|
2011-09-02 |
2019-10-09 |
The Regents of The University of California |
Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
EP2755648B1
(en)
|
2011-09-13 |
2017-03-08 |
Pharmacyclics LLC |
Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
|
JP2014534228A
(ja)
|
2011-11-02 |
2014-12-18 |
シンタ ファーマシューティカルズ コーポレーション |
白金含有剤とhsp90阻害剤の組合せ療法
|
JP2014532712A
(ja)
|
2011-11-02 |
2014-12-08 |
シンタ ファーマシューティカルズ コーポレーション |
トポイソメラーゼi阻害剤とhsp90阻害剤の組合せを使用する癌療法
|
JP2014533299A
(ja)
|
2011-11-14 |
2014-12-11 |
シンタ ファーマシューティカルズ コーポレーション |
Braf阻害剤とhsp90阻害剤の組合せ療法
|
CA2856291C
(en)
|
2011-11-17 |
2020-08-11 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of c-jun-n-terminal kinase (jnk)
|
CN104039321B
(zh)
|
2011-11-18 |
2017-02-22 |
赫普泰雅治疗有限公司 |
药物化合物
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
US9458162B2
(en)
*
|
2012-01-31 |
2016-10-04 |
Nanjing Allgen Pharma Co. Ltd. |
Cyclic molecules as bruton's tyrosine kinase inhibitors
|
US20150025077A1
(en)
|
2012-02-29 |
2015-01-22 |
Coyote Pharmaceuticals, Inc. |
Gga and gga derivatives compositions thereof and methods for treating neurodegenerative diseases including paralysis including them
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US9193733B2
(en)
|
2012-05-18 |
2015-11-24 |
Incyte Holdings Corporation |
Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
|
KR101972990B1
(ko)
|
2012-05-31 |
2019-04-26 |
파마사이언스 인크. |
단백질 키나제 저해제
|
NZ731932A
(en)
|
2012-06-04 |
2018-09-28 |
Pharmacyclics Llc |
Crystalline forms of a bruton’s tyrosine kinase inhibitor
|
US8828998B2
(en)
|
2012-06-25 |
2014-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
|
GB201211309D0
(en)
*
|
2012-06-26 |
2012-08-08 |
Fujifilm Mfg Europe Bv |
Process for preparing membranes
|
KR20150032340A
(ko)
|
2012-07-24 |
2015-03-25 |
파마시클릭스, 인코포레이티드 |
브루톤 티로신 키나제(btk)의 억제제에 대한 내성과 관련된 돌연변이
|
US9604988B2
(en)
|
2012-07-27 |
2017-03-28 |
Riken |
Agent for treating or inhibiting recurrence of acute myeloid leukemia
|
AU2013323426A1
(en)
|
2012-09-26 |
2015-04-23 |
The Regents Of The University Of California |
Modulation of ire1
|
US9119808B1
(en)
|
2012-10-08 |
2015-09-01 |
Coyote Pharmaceuticals, Inc. |
Treating neurodegenerative diseases with GGA or a derivative thereof
|
EP2909194A1
(en)
|
2012-10-18 |
2015-08-26 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
USRE48175E1
(en)
*
|
2012-10-19 |
2020-08-25 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
US10000483B2
(en)
|
2012-10-19 |
2018-06-19 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
|
CN104854107A
(zh)
|
2012-11-15 |
2015-08-19 |
药品循环公司 |
作为激酶抑制剂的吡咯并嘧啶化合物
|
US10166191B2
(en)
|
2012-11-15 |
2019-01-01 |
Incyte Corporation |
Sustained-release dosage forms of ruxolitinib
|
WO2014113942A1
(en)
|
2013-01-23 |
2014-07-31 |
Merck Sharp & Dohme Corp. |
Btk inhibitors
|
WO2014122474A1
(en)
|
2013-02-07 |
2014-08-14 |
Takeda Pharmaceutical Company Limited |
Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists
|
MX2020003446A
(es)
|
2013-03-06 |
2021-07-29 |
Incyte Holdings Corp |
Procesos e intermedios para hacer un inhibidor de jak.
|
EP2964260A2
(en)
|
2013-03-06 |
2016-01-13 |
F. Hoffmann-La Roche AG |
Methods of treating and preventing cancer drug resistance
|
TWI629275B
(zh)
*
|
2013-03-13 |
2018-07-11 |
賽諾菲公司 |
N-(4-(氮雜吲唑-6-基)-苯基)-磺醯胺及其作為醫藥之用途
|
US9481667B2
(en)
|
2013-03-15 |
2016-11-01 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
US9724354B2
(en)
|
2013-03-22 |
2017-08-08 |
Millennium Pharmaceuticals, Inc. |
Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
TWI649081B
(zh)
|
2013-08-02 |
2019-02-01 |
製藥公司 |
治療固態腫瘤之方法
|
PE20160223A1
(es)
|
2013-08-07 |
2016-04-27 |
Incyte Corp |
Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1
|
JP6429292B2
(ja)
|
2013-08-12 |
2018-11-28 |
ファーマサイクリックス エルエルシー |
Her2増幅性癌の処置のための方法
|
PE20160560A1
(es)
|
2013-09-30 |
2016-06-09 |
Pharmacyclics Llc |
DERIVADOS DE PIRAZOLO[3,4-d]PIRIMIDIN COMO INHIBIDORES IRREVERSIBLES DE LA TIROSINA CINASA DE BRUTON (BTK)
|
SG10201902074UA
(en)
|
2013-10-04 |
2019-04-29 |
Infinity Pharmaceuticals Inc |
Heterocyclic compounds and uses thereof
|
US9751888B2
(en)
|
2013-10-04 |
2017-09-05 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
CN105849099B
(zh)
|
2013-10-18 |
2020-01-17 |
达纳-法伯癌症研究所股份有限公司 |
周期蛋白依赖性激酶7(cdk7)的多环抑制剂
|
EP3057955B1
(en)
|
2013-10-18 |
2018-04-11 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of prolferative diseases
|
MX2021009400A
(es)
|
2013-10-25 |
2022-05-17 |
Pharmacyclics Llc |
Uso de ibrutinib en el tratamiento de enfermedad injerto contra huesped cronica.
|
US10328080B2
(en)
|
2013-12-05 |
2019-06-25 |
Acerta Pharma, B.V. |
Therapeutic combination of PI3K inhibitor and a BTK inhibitor
|
EP3079683A4
(en)
|
2013-12-13 |
2017-12-20 |
Dana-Farber Cancer Institute, Inc. |
Methods to treat lymphoplasmacytic lymphoma
|
US10272083B2
(en)
|
2014-01-21 |
2019-04-30 |
Acerta Pharma B.V. |
Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
|
BR112016016844A2
(pt)
*
|
2014-02-03 |
2017-08-08 |
Cadila Healthcare Ltd |
Compostos heterocíclicos
|
JP2017512183A
(ja)
|
2014-02-13 |
2017-05-18 |
リガンド・ファーマシューティカルズ・インコーポレイテッド |
プロドラッグ化合物およびそれらの使用
|
US9775844B2
(en)
|
2014-03-19 |
2017-10-03 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
JP2017509336A
(ja)
|
2014-03-20 |
2017-04-06 |
ファーマサイクリックス エルエルシー |
ホスホリパーゼcガンマ2及び耐性に関連した変異
|
WO2015181633A2
(en)
|
2014-04-11 |
2015-12-03 |
Acerta Pharma B.V. |
Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bruton's tyrosine kinase
|
US20150320755A1
(en)
|
2014-04-16 |
2015-11-12 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
WO2015164604A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged janus kinase inhibitors and uses thereof
|
US10017477B2
(en)
|
2014-04-23 |
2018-07-10 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
WO2015184305A1
(en)
|
2014-05-30 |
2015-12-03 |
Incyte Corporation |
TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
|
GB201410430D0
(en)
|
2014-06-11 |
2014-07-23 |
Redx Pharma Ltd |
Compounds
|
US20230190750A1
(en)
|
2014-06-13 |
2023-06-22 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
WO2015193740A2
(en)
|
2014-06-17 |
2015-12-23 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor, a pi3k inhibitor and/or a jak-2 inhibitor
|
CN106999494A
(zh)
|
2014-08-01 |
2017-08-01 |
药品循环有限公司 |
布鲁顿酪氨酸激酶的抑制剂
|
SG11201700849XA
(en)
|
2014-08-07 |
2017-03-30 |
Pharmacyclics Llc |
Novel formulations of a bruton's tyrosine kinase inhibitor
|
TW201618772A
(zh)
|
2014-08-11 |
2016-06-01 |
艾森塔製藥公司 |
Btk抑制劑、pi3k抑制劑、jak-2抑制劑及/或bcl-2抑制劑之治療組合物
|
WO2016054491A1
(en)
|
2014-10-03 |
2016-04-07 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US10196397B2
(en)
|
2014-11-19 |
2019-02-05 |
Sun Pharmaceutical Industries Limited |
Process for the preparation of ibrutinib
|
AU2015371251B2
(en)
|
2014-12-23 |
2020-06-11 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (CDK7)
|
WO2016106628A1
(en)
*
|
2014-12-31 |
2016-07-07 |
Merck Sharp & Dohme Corp. |
Btk inhibitors
|
CA3002540C
(en)
|
2015-01-06 |
2023-11-07 |
Arena Pharmaceuticals, Inc. |
Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
|
WO2016115869A1
(zh)
*
|
2015-01-21 |
2016-07-28 |
中国科学院合肥物质科学研究院 |
Flt3激酶的新型抑制剂及其用途
|
CN105481862B
(zh)
*
|
2015-01-21 |
2018-08-21 |
中国科学院合肥物质科学研究院 |
Flt3激酶的新型抑制剂及其用途
|
CA3177995A1
(en)
|
2015-03-03 |
2016-09-09 |
Pharmacyclics Llc |
Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor
|
US10550121B2
(en)
|
2015-03-27 |
2020-02-04 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
MA41828A
(fr)
*
|
2015-03-27 |
2018-01-30 |
Pharmacyclics Llc |
Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton
|
WO2016161248A1
(en)
*
|
2015-04-02 |
2016-10-06 |
Tolero Pharmaceuticals, Inc. |
Targeting pim kinases in combination with btk inhibition
|
EP3307728A4
(en)
|
2015-06-12 |
2019-07-17 |
Dana Farber Cancer Institute, Inc. |
ASSOCIATION THERAPY USING TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS
|
AU2016284162A1
(en)
|
2015-06-22 |
2018-02-01 |
Arena Pharmaceuticals, Inc. |
Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(Compound1) for use in SIP1 receptor-associated disorders
|
MD3317281T2
(ro)
|
2015-07-02 |
2020-07-31 |
Acerta Pharma Bv |
Forme solide și formulări de (S)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-α]pirazin-1-il)-N-(piridin-2-il)benzamidă
|
GB201513743D0
(en)
|
2015-08-03 |
2015-09-16 |
Heptares Therapeutics Ltd |
Muscarinic agonists
|
EP4019515A1
(en)
|
2015-09-09 |
2022-06-29 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
CN108349985A
(zh)
|
2015-09-14 |
2018-07-31 |
无限药品股份有限公司 |
异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
|
AU2016322063A1
(en)
|
2015-09-16 |
2018-04-12 |
Loxo Oncology, Inc. |
Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer
|
JP6731483B2
(ja)
|
2015-12-16 |
2020-07-29 |
ロクソ オンコロジー, インコーポレイテッドLoxo Oncology, Inc. |
キナーゼ阻害剤として有用な化合物
|
EA201891626A1
(ru)
|
2016-01-21 |
2019-04-30 |
Зибо Биополар Чангшенг Фармасьютикал Ко. Лтд. |
Ингибиторы тирозинкиназы брутона
|
US10793566B2
(en)
|
2016-01-21 |
2020-10-06 |
Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. |
Bruton's tyrosine kinase inhibitors
|
CA3016364A1
(en)
|
2016-03-03 |
2017-09-08 |
Bayer Pharma Aktiengesellschaft |
New 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs
|
KR102416971B1
(ko)
|
2016-03-11 |
2022-07-04 |
엔젤 파마슈티칼 컴퍼니, 리미티드 |
브루톤형 티로신 키나제를 조절하기 위한 화합물 및 방법
|
US10759806B2
(en)
|
2016-03-17 |
2020-09-01 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
|
JP2019518006A
(ja)
|
2016-04-29 |
2019-06-27 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
Myd88変異型疾患における治療標的としてのhck
|
CN105820184A
(zh)
*
|
2016-05-06 |
2016-08-03 |
蚌埠中实化学技术有限公司 |
一种4-苯氧基苯硼酸的制备方法
|
WO2017214269A1
(en)
|
2016-06-08 |
2017-12-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
SG10201912456RA
(en)
|
2016-06-24 |
2020-02-27 |
Infinity Pharmaceuticals Inc |
Combination therapies
|
GB201617454D0
(en)
|
2016-10-14 |
2016-11-30 |
Heptares Therapeutics Limited |
Pharmaceutical compounds
|
RU2019121527A
(ru)
|
2016-12-23 |
2021-01-15 |
Эрвинэс Оперейшнс, Инк. |
Химерные молекулы, нацеливающиеся на протеолиз egfr, и связанные с ними способы применения
|
CN110546133A
(zh)
|
2017-02-03 |
2019-12-06 |
塞尔塔治疗有限公司 |
抗纤维化化合物
|
CN110520124A
(zh)
|
2017-02-16 |
2019-11-29 |
艾尼纳制药公司 |
用于治疗原发性胆汁性胆管炎的化合物和方法
|
US10501449B2
(en)
|
2017-06-01 |
2019-12-10 |
Bristol-Myers Squibb Company |
Substituted nitrogen containing compounds
|
SG11202000839TA
(en)
|
2017-08-14 |
2020-02-27 |
Epizyme Inc |
Methods of treating cancer by inhibiting setd2
|
CN107550905B
(zh)
*
|
2017-09-11 |
2020-07-17 |
浙江永宁药业股份有限公司 |
多取代吡咯并吡啶类化合物的药物用途及其制备方法
|
US10596161B2
(en)
|
2017-12-08 |
2020-03-24 |
Incyte Corporation |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
WO2019130470A1
(ja)
*
|
2017-12-27 |
2019-07-04 |
株式会社ルネッサンス・エナジー・リサーチ |
Co2除去方法及び装置
|
EP3737676B1
(en)
|
2018-01-09 |
2024-03-06 |
Ligand Pharmaceuticals, Inc. |
Acetal compounds and therapeutic uses thereof
|
MA51771B1
(fr)
|
2018-01-30 |
2022-03-31 |
Incyte Corp |
Procédés de préparation de (1-(3-fluoro-2-(trifluorométhyl)isonicotinyl)pipéridine-4-one)
|
CA3095487A1
(en)
|
2018-03-30 |
2019-10-03 |
Incyte Corporation |
Treatment of hidradenitis suppurativa using jak inhibitors
|
GB201810239D0
(en)
|
2018-06-22 |
2018-08-08 |
Heptares Therapeutics Ltd |
Pharmaceutical compounds
|
JP2021536428A
(ja)
*
|
2018-08-14 |
2021-12-27 |
エピザイム,インコーポレイティド |
置換インドール及びその使用方法
|
US11427591B2
(en)
|
2018-10-17 |
2022-08-30 |
Insilico Medicine Ip Limited |
Kinase inhibitors
|
JP2022506957A
(ja)
|
2018-11-12 |
2022-01-17 |
デバイオファーム インターナショナル エス.エー. |
抗生物質化合物、それを製造する方法、それを含む医薬組成物及びその使用
|
GB201819960D0
(en)
|
2018-12-07 |
2019-01-23 |
Heptares Therapeutics Ltd |
Pharmaceutical compounds
|
CN111454268B
(zh)
*
|
2019-01-18 |
2023-09-08 |
明慧医药(上海)有限公司 |
作为布鲁顿酪氨酸激酶抑制剂的环状分子
|
CA3131388A1
(en)
*
|
2019-02-27 |
2020-09-03 |
Richard Keenan |
Pyrazolopyridine compounds for ire1 inhibition
|
GB202020191D0
(en)
|
2020-12-18 |
2021-02-03 |
Heptares Therapeutics Ltd |
Pharmaceutical compounds
|
CN118027041A
(zh)
*
|
2019-05-31 |
2024-05-14 |
西藏海思科制药有限公司 |
一种btk抑制剂环衍生物及其制备方法和药学上的应用
|
CN110511225B
(zh)
*
|
2019-08-19 |
2023-07-18 |
杭州中美华东制药有限公司 |
一种伊布替尼中间体的合成方法
|
WO2021038540A1
(en)
|
2019-08-31 |
2021-03-04 |
Sun Pharma Advanced Research Company Limited |
Cycloalkylidene carboxylic acids and derivatives as btk inhibitors
|
AU2020436612A1
(en)
*
|
2020-03-16 |
2022-09-01 |
Flash Therapeutics, Llc |
Compounds for treating or inhibiting recurrence of acute myeloid leukemia
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
WO2022081512A1
(en)
*
|
2020-10-12 |
2022-04-21 |
Synubi Pharmaceuticals Llc |
Compositions and methods of treatment of neuroinflammatory diseases with bruton's tyrosine kinase inhibitors
|
IL302807A
(en)
|
2020-11-18 |
2023-07-01 |
Deciphera Pharmaceuticals Llc |
GCN2 and PERK kinase inhibitors and methods of using them
|
CN114751927B
(zh)
*
|
2022-03-08 |
2023-10-31 |
中山大学 |
一种硼酸化合物、制备方法及用途
|
CN115124486B
(zh)
*
|
2022-07-07 |
2024-07-23 |
武汉理工大学 |
苯并噁唑衍生物及其制备方法与应用
|